BRCA1 and ovarian serous adenocarcinoma: To investigate how to overcome acquired PARPi resistance in BRCA mutant ovarian cancer cells, we used a well-established human high grade serous ovarian cancer cell line containing a frameshift germline BRCA1 mutation (UWB1.289, hereafter referred to as UWB1).